|Articles|October 15, 2002
- BioPharm International-10-01-2002
- Volume 15
- Issue 10
Virus Inactivation in the 1990s ? and into the 21st Century: Part 3b, Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent)
Author(s)Gail Sofer
by Gail Sofer, BioReliance The latest installment of our series on recently published methods for inactivating viruses reviews the literature on virus inactivation in plasma and plasma products by chemical treatments, gamma and UV irradiation, and low-pH treatment.
Advertisement
Articles in this issue
over 23 years ago
FDA Launches Major CGMP Reviewover 23 years ago
Process Validation: How Much to Do and When to Do Itover 23 years ago
Biotech Will Recover!over 23 years ago
GMPs and Pharmaceutical Labelingover 23 years ago
Revolutionizing Biologics RegulationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Coya Raises $11.1 Million to Advance Immunomodulatory ALS Program
2
FAQ: What You Need to Know About Agentic AI in Drug Discovery
3
AstraZeneca’s $15 Billion Investment Deepens China R&D and Manufacturing Footprint
4
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
5
